Reagents and instruments for immunology, cell biology and molecular biology.
 
> Newsletter > New technology to characterize cancers: R&D, preclinical and clinical studies

New technology to characterize cancers: R&D, preclinical and clinical studies

 

 

RT MLPSEQ

A new technology to characterize cancers

Gene expression and fusion transcripts
 

The RT-MLPSeq custom solution from Quimigen and GeneXpath allows you to assess the mRNA expression level or the presence of fusion transcripts of 10 to 100 markers of interest of your choice.

In research projects, preclinical and clinical studies, it is often necessary to obtain the gene expression or the presence of fusion transcripts of several dozen markers. At present, relative expression and fusion transcripts can only be analyzed with a small number of genes simultaneously, using complicated protocols. In addition, manipulation times are often very long, and solutions on the market are often expensive.

Genexpath's custom panel solution enables you to select your markers of interest quickly and easily. We then provide you with a turnkey solution: an in Vitro test and a bioinformatic analysis after a NGS sequencing.

These custom panels can be produced for any type of genome. We are at your disposal to produce panels of between ten and a hundred markers.
RT-MLPSEQ advantages
/upload/picture-for-categories-4-jqdec3.jpg    
  • Simple and fast protocol: ½ day manipulations.
  • Small quantity of material required: Only 50 and 500 ng of RNA needed. RNA from fresh, frozen or FFPE samples (tissue, liquid,... ): Optimized for difficult samples (FFPE).
  • No purification is required until the libraries are obtained: Limits material losses and ensures excellent sensitivity.
  • Robustness of the technique. 
RT-MLPSeq technology is already being used in oncology diagnostic kits for:

/upload/picture-for-categories-2-sbfxe3.jpg
  • Characterisation of non-Hodgkin's lymphomas: according to the WHO classification, by precise measurement of the expression signature of more than 130 genes of interest with our LymphoSign test (CE-IVD).
  • Characterisation of peripheral T-cell lymphomas: by analysing fusion transcripts using our LymphoTranscript test.
  • Characterisation of sarcomas: by analysing over 140 fusion transcripts using our SarcomaFusion test (CE-IVD).    

RT-MLPSEQ: A simple and rapid protocol

The robustness of our technology and our experience in diagnostics mean we can support you from R&D right through to companion diagnostics.
/upload/picture-for-categories--vz9q2z.jpg    
  • The in vitro test is made up of 4 steps lasting 1/2 day, including 1h to 1h30 of actual handling.
  • The NGS sequencing part requires just 100,000 reads per sample.
  • What's more, you can sequence test samples with other libraries, and barcodes are supplied with the kit.
  • These tests save you time in your projects.

 

Interested in more details? You can read more in our brochures!

Lymphoma Diagnosis

     

SarcomaFusion Detection
 

Should you have any questions or need assistance, feel free to contact our Business Development and Innovation Gael Gesbert.

 

/upload/picture-for-categories-11-vhfkvp.png

/upload/picture-for-categories-10-umpdvv.png